| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000037062 |
| Receipt No. | R000042198 |
| Scientific Title | Study on evaluation of reduction effect of test supplement on body fat -a randomized, double blind, placebo controlled, parallel group comparison study- |
| Date of disclosure of the study information | 2019/06/14 |
| Last modified on | 2020/06/12 (Ver. 5) |
| Basic information | ||
| Public title | Study on evaluation of reduction effect of test supplement on body fat -a randomized, double blind, placebo controlled, parallel group comparison study- | |
| Acronym | Body fat reduction effect of test supplement | |
| Scientific Title | Study on evaluation of reduction effect of test supplement on body fat -a randomized, double blind, placebo controlled, parallel group comparison study- | |
| Scientific Title:Acronym | Body fat reduction effect of test supplement | |
| Region |
|
|
| Condition | |||
| Condition | Healthy subject | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | This study aimed to assess the effect of test supplement on body fat. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Abdominal visceral fat area |
| Key secondary outcomes | Abdominal total fat area, abdominal subcutaneous fat area, body weight, BMI, waist circumference, hip circumference, ratio of waist and hip circumferences, subgroup analysis (BMI, abdominal visceral fat area, sex, defecation frequency) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test supplement for 12 consecutive weeks | |
| Interventions/Control_2 | Intake of placebo for 12 consecutive weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Japanese male and female whose age is between 45 and 70 years old
2. Subjects whose BMI is between 23 and 30 |
|||
| Key exclusion criteria | 1. Subjects who are currently under medical treatment, diet therapy or exercise therapy.
2. Subjects who are under treatment or have a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease, abnormal secretion disease of adrenocortical hormone) 3. Subjects with allergies to the test food in this study 4. Females who are known or suspected to be pregnant, breastfeeding or desire to become pregnant during the trial period. 5. Subjects who routinely use some medicine, health foods affecting body fat or lipid metabolism. 6. Subjects who currently are dieting. 7. Subjects who have participated in other clinical study within the past month prior. 8. Subjects who use some medicine, food containing lactic acid bacteria or polymethoxyflavone 3 days a week or more from half a year before the informed consent. 9. Subjects who are judges as unsuitable for the study based on the results of lifestyle questionnaire 10. Subjects who are judged as unsuitable for the study based on the results of clinical laboratory test or cardiopulmonary function. 11. Subjects who have diseases requiring continuous medication, or serious medical history who needed medication therapy 12. Subjects who always use laxative when defecation. 13. Subjects who have taken antibiotics within the past month 14. Subjects who are judged as unsuitable for the study based on the results of clinical laboratory test or physical examination. 15. Subjects who are planning to travel abroad during the study period, or who are planning of long term domestic trip for more than one week in study period. 16. Subjects who are judged as unsuitable for the study by the investigator for other reason |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | FANCL Corporation | ||||||
| Division name | Research Institute, Health science research center | ||||||
| Zip code | 244-0806 | ||||||
| Address | 12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa | ||||||
| TEL | 045-820-3755 | ||||||
| ke-yui@fancl.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TTC Co., Ltd. | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 150-0021 | ||||||
| Address | 1-20-2, Ebisu-nishi, Shibuya-ku, Tokyo, Japan | ||||||
| TEL | 03-5459-5329 | ||||||
| Homepage URL | |||||||
| s.yamamichi@ttc-tokyo.co.jp | |||||||
| Sponsor | |
| Institute | TTC Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | FANCL Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Aisei Hospital Ueno Clinic Research Ethics Committee |
| Address | 2-18-6, Higashiueno, Taitou-ku, Tokyo |
| Tel | 03-6455-0880 |
| t.saito@ttc-smo.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 104 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042198 |